Hong Kong Baptist University - Hong Kong
AUTHOR PROFILE
Scopus
Orcid
EARLY ACADEMIC PURSUITS
Kwan Hiu Yee's academic journey began with a strong foundation in the sciences. She earned a B.Sc. with 2nd Honors Upper Class in Biology and Biotechnology from the Faculty of Science at The University of Hong Kong (1992-1995).
PROFESSIONAL ENDEAVORS
Continuing her academic pursuits, Kwan Hiu Yee completed her Ph.D. at the Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong (2001-2006). She further honed her expertise by obtaining a Certificate in Epidemiology & Control of Infectious Diseases from the School of Public Health at The Chinese University of Hong Kong in 2005.
Kwan Hiu Yee's research focus has been on the intersection of physiology, public health, and Chinese medicine. Her contributions extend to the exploration of vascular ion channel targets in cardiovascular diseases, as evidenced by winning the Second Prize of China Medical Science and Technology Award in 2020.
IMPACT AND INFLUENCE
As an Associate Professor and Associate Director in the Teaching and Research Division at the Centre for Cancer & Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kwan Hiu Yee plays a pivotal role in shaping the academic landscape.
ACADEMIC CITES
Her impactful work is reflected in numerous academic accolades, including the CUHK Young Scholars Dissertation Awards nomination in 2007 and the HKBU School Performance Award in Teaching in 2022.
LEGACY AND FUTURE CONTRIBUTIONS
Kwan Hiu Yee's legacy is marked by her active involvement in professional memberships, such as the International Society for Extracellular Vesicles and the Hong Kong Association for the Study of Obesity and Cancer. With a diverse skill set, including a Master of Arts in Translation & Linguistics, she continues to contribute to academia.
NOTABLE PUBLICATIONS
Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. 2024
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis. 2024
Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. 2023 (3)
Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. 2022 (6)
Omics approach to reveal the effects of obesity on the protein profiles of the exosomes derived from different adipose depots. 2022